SA PRO
Free Account
Amneal Pharmaceuticals, Inc.AMRXNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating
Buy
15 analysts·Moderate coverage
67%
Rating Distribution
Strong Buy
00%
Buy
1067%
Hold
533%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 7, 2026Truist Financial
Amneal Pharmaceuticals price target raised to $15 from $14 at Truist
Target:$15.00
+15.5%from $12.99
Dec 8, 2025Barclays
Amneal Pharmaceuticals initiated with an Overweight at Barclays
Target:$15.00
+26.4%from $11.87
Mar 3, 2025Barclays
Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays
Target:$11.00
+25.6%from $8.76
Nov 11, 2024Piper Sandler
Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler
Target:$11.00
+32.7%from $8.29
Oct 2, 2024Truist Financial
Amneal Pharmaceuticals price target raised to $12 from $10 at Truist
Target:$12.00
+37.9%from $8.70
Oct 1, 2024Truist Financial
Truist Securities Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX)
Target:$10.00
+14.9%from $8.70
May 3, 2024Truist Financial
Amneal Pharmaceuticals (AMRX) PT Raised to $9 at Truist Securities
Target:$9.00
+33.1%from $6.76
Mar 21, 2024Piper Sandler
Amneal Pharmaceuticals (AMRX) PT Raised to $8 at Piper Sandler
Target:$8.00
+27.2%from $6.29
Aug 8, 2022Goldman Sachs
Goldman Sachs Maintains Buy on Amneal Pharmaceuticals, Lowers Price Target to $4
Target:$4.00
+24.2%from $3.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance